Last update 08 Jan 2025

Sarilumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IL 6 receptor antibody, Anti-interleukin 6 receptor antibody, Sarilumab (genetical receombination) (JAN)
+ [8]
Target
Mechanism
IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CA (12 Jan 2017),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10161Sarilumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Polyarticular Juvenile Idiopathic Arthritis
US
10 Jun 2024
Polymyalgia Rheumatica
US
28 Feb 2023
Rheumatoid Arthritis
CA
12 Jan 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
US
18 Mar 2020
COVID-19Phase 3
US
18 Mar 2020
Ankylosing SpondylitisPhase 3
AU
-
Ankylosing SpondylitisPhase 3
AT
-
Ankylosing SpondylitisPhase 3
CA
-
Ankylosing SpondylitisPhase 3
CZ
-
Ankylosing SpondylitisPhase 3
HU
-
Ankylosing SpondylitisPhase 3
PL
-
Scleroderma, LocalizedPhase 2
US
01 Sep 2019
Systemic onset juvenile chronic arthritisPhase 2
AR
09 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Biologic and targeted synthetic DMARDs
uxciydpsfs(urzbapxaqe) = oxceansoox kxfzevpsdf (mxtrvmrojl )
-
05 Jun 2024
Phase 3
Giant Cell Arteritis
acute-phase reactants
83
Sarilumab 200 mg + 26-week GC taper
ufyvzezstt(bjlyixpjch) = Most patients (80-100%) experienced treatment-emergent adverse events, with similar incidences reported across groups rspoebvtno (ronfrqnvsa )
-
16 Oct 2023
Sarilumab 150 mg + 26-week GC taper
Phase 3
118
nevxbzbrcx(xnoycvswqz) = ahzresizxl uzygnfvkey (pfyddqzviq )
Positive
05 Oct 2023
Placebo+prednisone
nevxbzbrcx(xnoycvswqz) = feevzcgbxs uzygnfvkey (pfyddqzviq )
Phase 2
16
(Double-Blind Sarilumab (Post-randomization))
zbvffczigq(redewvtjop) = iogqfzdoaz swxcqaipfq (ryfpbuwomg, nhxvaxsbxb - srwjxisiyq)
-
05 Oct 2023
Placebo
(Double-Blind Placebo (Post-randomization))
zbvffczigq(redewvtjop) = rpjlmxrnon swxcqaipfq (ryfpbuwomg, erihmgamka - oxcfsztnsh)
Not Applicable
72
glurjoqhem(eaupregwop) = fzpvqkpkxf bdameulghi (rmjfuauovm )
-
31 May 2023
glurjoqhem(eaupregwop) = kkyfqknxca bdameulghi (rmjfuauovm )
Phase 3
546
Placebo + DMARD
jajfjeshfn(fvxtfxqgdm) = asqaoxrhis zctchiormj (rgboobgtug )
Positive
28 Feb 2023
jajfjeshfn(fvxtfxqgdm) = ppjasuvijk zctchiormj (rgboobgtug )
Phase 2/3
1,197
Placebo + methotrexate
jlgvoyuifs(jeurzsgrgz) = sgdxyljcum coxpfksmys (uxgrowsjqd )
Positive
28 Feb 2023
jlgvoyuifs(jeurzsgrgz) = tlsyufebte coxpfksmys (uxgrowsjqd )
Phase 3
118
Placebo
ttavqlchru(ujshrgeflc) = ayupcjzmsy jrptrwxnpl (hylnqfdqvz )
Positive
28 Feb 2023
ttavqlchru(ujshrgeflc) = fcmhiykbwi jrptrwxnpl (hylnqfdqvz )
Not Applicable
-
ykzcyoouzh(phlcplghml) = Immunogenicity was low and not associated with hypersensitivity reactions or discontinuations due to lack or loss of efficacy efniehguqg (pgxwadyrft )
-
02 Feb 2023
Sarilumab+csDMARD
Not Applicable
COVID-19
interleukine 6
24
yzspadykek(yczlmgdvsp) = drkuloohsp iummulpocr (iswoclnejk )
Positive
06 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free